Interventional × Myelodysplastic Syndromes × Biopsy × Clear all
NCT07046078 2026-01-30

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

Fred Hutchinson Cancer Center

Phase 2 Recruiting
20 enrolled
NCT05031897 2025-10-30

Two Step Haplo With Radiation Conditioning

Thomas Jefferson University

Phase 2 Recruiting
63 enrolled
NCT06712810 2025-10-10

Q702 for the Treatment of Patients With Hematologic Malignancies

Mayo Clinic

Phase 1 Recruiting
46 enrolled
NCT03017820 2025-10-08

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Mayo Clinic

Phase 1 Recruiting
127 enrolled
NCT06815003 2025-06-27

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

City of Hope Medical Center

Phase 2 Recruiting
35 enrolled
NCT00425477 2018-10-05

Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
26 enrolled 7 charts